Charles Ananian, DPM
Podiatrist · Los Angeles, CANPI 1033120787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,960 of the $68,644 with a category attached, or 64.0%. Smith+Nephew accounts for 69.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $31,202 and has fallen 96.4% since, to $1,138 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $105.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$48K
- Osiris Therapeutics Inc.$15K
- Organogenesis Inc.$2K
- Treace Medical Concepts, Inc.$705
- Angiodynamics, Inc.$698
- Medtronic$647
- plus $2K from 24 others
Across 14 payments — averaging $4832.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Reddress LTD$49K
- Globus Medical$11K
- Axogen$5K
- Osiris Therapeutics Inc.$2K
What the payments were for
- Consulting fees$3,9606%
- Speaking & faculty fees$43,96064%
- Travel & lodging$3,4715%
- Food & beverage$17,25425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 395 | $47,841 |
| Osiris Therapeutics Inc. | 96 | $15,143 |
| Organogenesis Inc. | 84 | $1,840 |
| Treace Medical Concepts, Inc. | 2 | $705 |
| Angiodynamics, Inc. | 7 | $698 |
| Medtronic | 4 | $647 |
| Stryker(2 entities) | 4 | $426 |
| KCI USA, Inc. | 3 | $158 |
| Integra Lifesciences Corporation | 5 | $157 |
| Amgen | 1 | $118 |
| Merck | 11 | $110 |
| AbbVie | 5 | $101 |
| Paratek Pharmaceuticals, Inc. | 5 | $91 |
| Urgo Medical North America, LLC | 2 | $79 |
| Cardiovascular Systems Inc. | 1 | $76 |
| Nevro Corp. | 3 | $64 |
| Biotissue Holdings Inc. | 3 | $52 |
| Convatec Inc. | 2 | $50 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Zimmer Biomet | 1 | $40 |
| Polarityte, Inc. | 1 | $36 |
| Amniox Medical, Inc. | 3 | $33 |
| Averitas Pharma Inc. | 1 | $25 |
| Checkpoint Surgical, Inc | 1 | $23 |
| Next Science LLC | 1 | $19 |
| DJO, LLC | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Innovation Technologies Inc | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
| Orthofix Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stravix$36,283
- Grafix$31,884
- Grafix XC$24,589
- GRAFIX PL$24,582
- GrafixPL$19,464
- STRAVIX PL$16,701
- Grafix PL PRIME$6,950
- Oasis$6,005
- Grafix PRIME$5,700
- Grafix CORE$5,700
- Lapiplasty System$705
- PuraPly$463
- Auryon Laser System 100-120 Vac$378
- INTELLIS ADAPTIVESTIM$345
- INCEPTIV$157
- Accurian$145
- NONE$144
- Actishield$143
- SNAP$125
- ACTIVAC$125
How this compares
$68,644 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 72 | $60,355 |
| RegranexBecaplermin | 32 | $39,516 |
| Ketoconazole | 472 | $13,129 |
| Clotrimazole | 389 | $12,413 |
| Fluocinonide | 80 | $4,316 |
| SsdSilver Sulfadiazine | 342 | $3,888 |
| Diclofenac Sodium | 81 | $3,764 |
| Ciclopirox | 93 | $2,478 |
| Ammonium Lactate | 229 | $2,235 |
| Vancomycin Hcl | 12 | $2,085 |
| Terbinafine Hcl | 122 | $1,335 |
| Silver Sulfadiazine | 93 | $1,260 |
| Econazole Nitrate | 26 | $1,060 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 151 | $1,032 |
| Triamcinolone Acetonide | 95 | $891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl, Regranex | $47,841 | $99,871104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 721 podiatrist providers in California.
Other podiatrist in Los Angeles
- David ArmstrongLos Angeles$695K
- Edward KimLos Angeles$48K
- Benjamin McGrathLos Angeles$25K
- Laura ShinLos Angeles$20K
- Renato SousaLos Angeles$14K
- Megan IshibashiLos Angeles$10K
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.